AKBA Q3 2023 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M-13.7% YoY

Gross Profit

$24M57.2% margin

Operating Income

-$13M-31.0% margin

Net Income

-$14M-34.5% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-25.4%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$235M

Total Liabilities

$274M

Stockholders' Equity

-$39M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$49M	-13.7%
Gross Profit	$24M	$10M	+130.4%
Operating Income	-$13M	-$50M	+74.1%
Net Income	-$14M	-$54M	+73.2%

Revenue Segments

Product

$40M95%

License Collaboration And Other Revenue

$2M5%